



SATURDAY 7 SEPTEMBER 2019			
07:15	Industry Symposium - Eli Lilly 07:15 - 08:45		
09:00	<p>One Topic Two Views 7 - What is the reason behind the higher prevalence of migraine in females than in males? Is it genetics or hormonal fluctuations that are the main factor?</p> <p>09:00 - 10:00 Chair: B. Jenkins (Australia) 09:00-09:05 - Chairman introduction 09:05-09:25 - Differential expression of estrogen receptors in the trigeminovascular system male-female is the key behind higher prevalence of migraine in females (A. MacGregor, UK) 09:25-09:45 - Genetic differences between male and female is the main factor responsible for the higher numbers of migraine in female vs male (D. Nyholt, Australia) 09:45-10:00 - Discussion</p>	<p>One Topic Two Views 8 - Is migraine a CGRP disorder?</p> <p>09:00 - 10:00 Chair: A. Charles (USA) 09:00-09:05 - Chairman introduction 09:05-09:25 - CGRP pathway is integral to migraine pathophysiology (A. Russo, USA) 09:25-09:45 - Migraine is not a CGRP disorder (M. Ashina, Denmark). 09:45-10:00 - Discussion</p>	<p>One Topic Two Views 9 - Is the migraine cortex inherently hyperresponsive: re-examining the detected habituation system</p> <p>09:00-10:00 Chair: D. Borsook (USA) 09:00-09:05 - Chairman introduction 09:05-09:25 - The migraine brain is inheritably hyper-responsive (G. Coppola, Italy) 09:25-09:45 - The migraine brain is not inheritably hyperexcitable (T. Sand, Norway) 09:45 - 10:00 - Discussion</p>
10:00	Coffee break 10:00-10:30		
10:30	<p>Oral communications 1 10:30-11:30 Chairs: C. Ayata (USA) & M. Peres (Brazil)</p> <p>10:30-10:40 - IHC-OR-001 - Evaluation of genetic associations in a multicentre UK cohort of 880 Cluster Headache patients (E. O'Connor, UK) 10:40-10:50 - IHC-OR-002 - Molecular characterization of human trigeminal ganglia at single-cell resolution (W. Renthal, USA) 10:50-11:00 - IHC-OR-003 - Effects of Single pulse transcranial magnetic stimulation on the propagation of cortical spreading depression (J. Lloyd, UK) 11:00-11:10 - IHC-OR-004 - Efficacy, Safety, and Tolerability of Rimegepant 75 mg Orally Dissolving Tablet for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial, Study 303 (C. Conway, USA) 11:10-11:20 - IHC-OR-005 - PKC-5-positive cells in the central amygdala contribute to chronification of migraine in a mouse model (T-M Chou, Taiwan) 11:20-11:30 - IHC-OR-006 - Long-term efficacy and safety of erenumab: Results from 64 weeks of the LIBERTY study (U. Reuter, Germany)</p>	<p>Oral Communications 2 10:30-11:30 Chairs: L. Schulte (Germany) & A. Russo (USA)</p> <p>10:30-10:40 - IHC-OR-007 - Local Thalamic Inhibition and Migraine (I. Mehta, UK) 10:40-10:50 - IHC-OR-008 - Increased neural connectivity between the hypothalamus and cortical resting state functional networks in chronic migraine (V. Di Piero, Italy) 10:50-11:00 - IHC-OR-009 - Efficacy and safety of lasmiditan in patients on migraine preventive medications: findings from SAMURAI and SPARTAN Phase 3 trials (H-P Hundemer, Germany) 11:00-11:10 - IHC-OR-010 - Glyceryl trinitrate-induced non-headache symptoms indicative of an impending migraine-like attack: a case-control study (G. Onderwater, The Netherlands) 11:10-11:20 - IHC-OR-011 - PACAP-38 and PACAP(6-38) degranulate rat meningeal mast cells via the orphanMrgB3-receptor (L. Jansen-Olesen, Denmark) 11:20-11:30 - IHC-OR-012 - Very early onset of action of fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive treatments: results of the international, multicentre, randomised, placebo-controlled FOCUS study (J. Brandes, USA)</p>	<p>Oral Communications 3 10:30-11:30 Chairs: A. Ambrosini (Italy) & T. Schwedt (USA)</p> <p>10:30-10:40 - IHC-OR-013 - Inflammation as a risk factor for development of idiopathic intracranial hypertension (A. Sundholm, Sweden) 10:40-10:50 - IHC-OR-014 - Partial Similarity reveals dynamics in brainstem-midbrain networks during trigeminal nociception (J. Mehnert, Denmark) 10:50-11:00 - IHC-OR-015 - Ubrogepant is Effective for the Acute Treatment of Migraine in Patients with an Insufficient Response to Triptans (A. Blumenfeld, USA) 11:00-11:10 - IHC-OR-016 - Spontaneous cortical spreading depolarization and early mortality in an Scn1a-L263V familial hemiplegic migraine mouse model (N. Jansen, The Netherlands) 11:10-11:20 - IHC-OR-017 - Impaired parasympathetic modulation on heart rate variability in patients with chronic migraine (K-L Lai, Taiwan) 11:20-11:30 - IHC-OR-018 - HIT-6 Responder Rates after 1 and 3 Months of Eptinezumab Treatment (R. Cady, USA)</p>
11:30	<p>Scientific session 4 - The CGRP-mAbs hype: The benefits, the ethics, the finance and the role of the treating physician</p> <p>11:30 - 12:30 Chair: M. Levin (USA) 11:30-11:35 - Moderators introduction 11:35-11:55 - The Emperor's New Gepants and the disappearance of therapeutic gain: Disturbing ethical and moral views (E. Loder, USA) 11:55-12:15 - What justifies the CGRP-mAbs hype? What should we tell or not tell patients? Is it our responsibility to fight for lower cost of these drugs? (P. Pozo-Rosich, Spain) 12:15-12:30 - Audience discussion</p>		
12:30	<p>12:30 - 13:30 Chairs: A. Andreou (UK) & A. Sinclair (UK)</p> <p>12:30-12:35 - Introduction (A. Hougaard, Denmark) 12:35-12:42 - IHC-OR-019 - Alterations in functional connectivity during nitroglycerin (NTG)-triggered premonitory symptoms and migraine headache assessed using blood oxygen level dependant (BOLD) functional magnetic resonance imaging (fMRI) (N. Karsan, UK) 12:42-12:49 - IHC-OR-020 - Opening of ATP sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine (M. Al-Mahdi Al-Karagholi, Denmark) 12:49-12:56 - IHC-OR-021 - Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging (S. Khan, Denmark) 12:56-13:00 - Voting 13:00-13:07 - IHC-OR-022 - Differential Effects of Mu and Delta Opioid Receptor Agonists in Models of Chronic Migraine-Associated Pain and Aura (Z. Bertels, USA) 13:07-13:14 - IHC-OR-023 - Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache (C. Kopruszinski, USA) 13:14-13:21 - IHC-OR-024 - Central sites controlling CGRP-induced light-aversive behavior (L. Sowers, USA) 13:21-13:25 - Voting 13:25-13:30 - Awards (A. Hougaard, Denmark)</p>		
13:30	Break and lunch box collection 13:30-13:45		
13:45	<p>Lunch Session 4 - Triggers and prodromes 13:45 - 14:45 Chair: D. Buse (USA) 13:45-14:00 - The problem with migraine triggers: is there an explanation for lack of consistency (R. Lipton, USA) 14:00-14:15 - The problem with migraine prodromes: is there an explanation for lack of consistency (M. Matharu, UK) 14:15-14:30 - Can physiological studies help answer these questions? (E. Tolner, The Netherlands) 14:30-14:45 - Discussion</p>	<p>Lunch Session 5 - Non-invasive neuromodulators role in the treatment of migraine and cluster headache: do they work and how? 13:45 - 14:45 Chair: J. Pascual (Spain) 13:45-14:00 - Vagus nerve stimulation (S. Akerman, USA) 14:00-14:15 - Transcranial magnetic stimulation (A. Andreou, UK) 14:15 - 14:30 - Non-cranial nerve stimulators: (D. Yarnitsky, Israel) 14:30-14:45 - Discussion</p>	<p>Lunch Session 6 - Persistent idiopathic facial pain 13:45 - 14:45 Chair: T. Ward (USA) 13:45 - 13:55 - Chronic and episodic versions of orofacial pain: New concepts (A. May, Germany) 13:55 - 14:00 - Discussion 14:00-14:10 - Autoimmune facial pain: overlap between Neurology and Rheumatology (H. Ansari, USA) 14:10-14:15 - Discussion 14:15-14:25 - Differential diagnosis and treatment of temporomandibular disorders and trigeminal neuralgia (M. Romero-Reyes, USA) 14:25-14:30 - Discussion 14:30-14:40 - Atypical facial pain (D. Mitsikostas, Greece) 14:40-14:45 - Discussion</p>
14:45	Break and Poster Walk II 14:45 - 15:45		
15:45	Late Breaking Abstracts - Clinical Chair: D. Dodick (USA) 6 speakers, 7+3 15:45-16:45	Late Breaking Abstracts - Basic Chair: P. Holland (UK) 6 speakers, 7+3 15:45-16:45	
16:45	Cephalalgia Award Lecture Chair: A. May (Germany) 16:45-17:45		
17:45	Industry Symposium - Theranica 17:45 - 18:45		
18:45	IHS Juniors Open Meeting 18:45-19:15		
19:15	An opportunity for all IHS junior members to learn more about the IHS Juniors Group, influence our society, and make yourselves heard. Tickets to the Juniors Forum can be collected immediately after the meeting		

Exhibition Open
09:00 - 18:00

Colour Key	Sessions
Light Green	Teaching Courses
Light Blue	Plenary Sessions
Light Orange	Parallel Sessions
Light Purple	Industry Symposia
Light Yellow	Exhibition
Light Grey	AGM
Light Green	Oral Communications
Light Blue	Cephalalgia Award Lecture / Awards and Closing Ceremony
Light Orange	Coffee break / Lunch / Poster Walk
Light Purple	Social Activities